In view of this, no matter in all individuals or non‐HSCT subgroup, FLT3‐ITD carrier, age ≤ 3 years, and hyperleukocytosis could be regarded as independent adverse factors in AML‐M5 children. This evidence concerns the gene FLT3 and acute myeloid leukemia.